Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Takuya NishiInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.
Kunihiro HayakawaInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.ORCID 0000-0002-8053-746X
Keigo IkedaInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.ORCID 0000-0002-8032-7147
Maki FujishiroInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.
Yuko KataokaInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.
Ken YamajiDepartment of Internal Medicine and Rheumatology, School of Medicine, Juntendo University, Tokyo 113-8421, Japan.
Kenji TakamoriInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.ORCID 0000-0002-0644-0504
Naoto TamuraDepartment of Internal Medicine and Rheumatology, School of Medicine, Juntendo University, Tokyo 113-8421, Japan.ORCID 0000-0003-1729-2954
Iwao SekigawaInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.
Shinji MorimotoInstitute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka Urayasu-Shi, Chiba 279-0021, Japan.
Funding
Japan Society for the Promotion of Science (JSPS) JP22K09365 and JP19K09608The Ministry of Education, Culture, Sports, Science, and Technology (MEXT)-supported Program for the Strategic Research Foundation at Private University S1311011
6 · The paper itself
Abstract
Belimumab, a fully humanized B cell-activating factor (BAFF)-targeting monoclonal antibody, inhibits autoreactive B cell survival and improves systemic lupus erythematosus (SLE) clinical outcomes. However, its administration criteria remain unclear. To establish a basis for defining these criteria, we characterized the immune cell subpopulation alterations post-belimumab treatment and elucidated the underlying mechanisms. We hypothesized that belimumab modulates specific cell subsets and investigated the post-therapy changes. Flow cytometry and correlation analysis revealed that the frequency of B- and T-lymphocyte attenuator (BTLA)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
BTLA-Expressing Memory B Cells Are Associated with Belimumab-Induced Improvement in Systemic Lupus Erythematosus. · full record | OpenQuestion